1. Scrip

GSK’s Shingrix Vaccine Can Reach Millions More

US FDA Clears New Claim In Immunocompromised Adults

 
• By Brenda Sandburg

The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.

Shingles vaccine
US FDA approves Shingrix for use in immunocompromised adults • Source: Alamy

GlaxoSmithKline plc stands to significantly expand the market opportunity for its blockbuster shingles vaccine Shingrix (zoster vaccine recombinant, adjuvanted) with a new approval by the US Food and Drug Administration for prevention of shingles (herpes zoster) use in immunocompromised adults.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.